Skip to main content
Spero Therapeutics, Inc. logo

Spero Therapeutics, Inc. — Investor Relations & Filings

Ticker · SPRO ISIN · US84833T1034 LEI · 54930074G13LHWJT2323 US Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2018-07-09 Capital/Financing Update
Country US United States of America
Listing US SPRO

About Spero Therapeutics, Inc.

https://sperotherapeutics.com/

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections. The company's primary mission is to address the significant unmet medical needs caused by antibiotic resistance. Its pipeline includes tebipenem HBr, an oral carbapenem antibiotic candidate for the treatment of complicated urinary tract infections (cUTIs), which has completed a Phase 3 trial. Spero Therapeutics leverages its expertise in chemistry and microbiology, alongside strategic partnerships, to advance its portfolio of innovative therapies for serious infections.

Recent filings

Filing Released Lang Actions
S-1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, which is used for initial public offerings (IPOs) or other securities registration under the Securities Act of 1933. It includes detailed information about the company, the offering, risk factors, management, financial data, and underwriting details. This type of filing is related to capital raising activities and financing. It is not an annual report, earnings release, or any other type of financial or governance report. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is the actual registration statement, not just an announcement or summary.
2018-07-09 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The text indicates it is reporting interim data from a Phase 1 clinical trial and includes a press release and additional information as exhibits. There are no financial statements or detailed financial data presented, only announcements and disclosures. The document is about Regulation FD Disclosure and interim clinical trial data, which is typical for an 8-K filing. It is not an Annual Report, Earnings Release, or Interim Report with substantive financial data. Therefore, the filing type is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2018-07-09 English
FORM 4 SUBMISSION
Director's Dealing
2018-07-06 English
FORM 4 SUBMISSION
Director's Dealing
2018-07-06 English
FORM 4 SUBMISSION
Director's Dealing
2018-07-06 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 5, 2018, reporting on the submission of matters to a vote of stockholders at the company's 2018 annual meeting. It details the voting results for board director elections and the ratification of the independent auditor. The content focuses on official voting results from a shareholder meeting, which aligns with the category for Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 3319 characters, which is relatively short but contains substantive voting results, not just an announcement of a report. Therefore, it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). The primary content is the voting results, so the correct classification is DVA with high confidence.
2018-06-08 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.